Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS).

[1]  Qifu Li,et al.  Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP). , 2021, Science Bulletin.

[2]  Z. Ning,et al.  Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study , 2019, Clinical Drug Investigation.

[3]  Zuojie Luo,et al.  Efficacy and safety of chiglitazar in type 2 diabetes: a multi-center, randomized, double-blind, and parallel group clinical trial , 2019 .

[4]  H. Shamshad,et al.  Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. , 2019, European journal of medicinal chemistry.

[5]  M. Nieuwdorp,et al.  Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both? , 2018, Diabetes, obesity & metabolism.

[6]  B. Okopień,et al.  Benefits and risks of the treatment with fibrates––a comprehensive summary , 2018, Expert review of clinical pharmacology.

[7]  Wei Wang,et al.  Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ , 2017, PPAR research.

[8]  J. Eeckhoute,et al.  Distinct but complementary contributions of PPAR isotypes to energy homeostasis. , 2017, The Journal of clinical investigation.

[9]  R. Blankstein,et al.  Obesity, metabolic syndrome and cardiovascular prognosis: from the Partners coronary computed tomography angiography registry , 2017, Cardiovascular Diabetology.

[10]  K. Khunti,et al.  Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis , 2016, Diabetes, obesity & metabolism.

[11]  M. Lazar,et al.  Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. , 2014, Cell metabolism.

[12]  G. Umpierrez,et al.  Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5) , 2014, Diabetes Care.

[13]  D. Grobbee,et al.  Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. , 2014, JAMA.

[14]  M. Roden,et al.  Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. , 2013, The lancet. Diabetes & endocrinology.

[15]  A. Januszewicz,et al.  Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial , 2013, Diabetologia.

[16]  Z. Shen,et al.  In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist , 2012, PPAR research.

[17]  J. Peters,et al.  The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention , 2012, Nature Reviews Cancer.

[18]  P. Poirier,et al.  The cardiovascular effects of peroxisome proliferator-activated receptor agonists. , 2012, The American journal of medicine.

[19]  Dorothy D. Sears,et al.  Fat-induced inflammation unchecked. , 2010, Cell metabolism.

[20]  D. Rader,et al.  The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. , 2010, Atherosclerosis.

[21]  P. Sarafidis,et al.  Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  R. Arora,et al.  Cardiovascular Manifestations of Insulin Resistance , 2009, American journal of therapeutics.

[23]  S. Mudaliar,et al.  Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study , 2009, The Lancet.

[24]  S. Yusuf,et al.  Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose , 2008, Diabetes Care.

[25]  H. Bays,et al.  A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus , 2007, Diabetes & vascular disease research.

[26]  H. Berlie,et al.  Evolution of Peroxisome Proliferator-Activated Receptor Agonists , 2007, The Annals of pharmacotherapy.

[27]  R. DeFronzo,et al.  Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy , 2006, Diabetes Care.

[28]  M. Holness,et al.  Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase kinases , 2006, Archives of physiology and biochemistry.

[29]  Joseph L Evans,et al.  Novel Approach to Treat Insulin Resistance, Type 2 Diabetes, and the Metabolic Syndrome: Simultaneous Activation of PPARα, PPARγ, and PPARδ , 2005 .

[30]  A. Tenenbaum,et al.  Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons , 2005, Cardiovascular diabetology.

[31]  J. Buse,et al.  Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes , 2005 .

[32]  Alfonso T. Perez,et al.  A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. , 2005, Diabetes care.

[33]  B. Howard,et al.  Dyslipidemia of the metabolic syndrome , 2002, Current cardiology reports.

[34]  B. Staels,et al.  PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD , 2017, Nature Reviews Endocrinology.

[35]  V. Mohan,et al.  Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. , 2009, Diabetes research and clinical practice.